Gerardo Colón‐Otero

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Edith A. Perez, Edward H. Romond, Vera J. Suman et al. · Journal of Clinical Oncology · 2014 · 984 citations · Full text

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 839 citations · Full text

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 533 citations · Full text

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Pooja Advani, Karla V. Ballman, Travis Dockter et al. · Journal of Clinical Oncology · 2015 · 164 citations · Full text

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

Ayalew Tefferi, Hagop Kantarjian, S. Vincent Rajkumar et al. · Mayo Clinic Proceedings · 2015 · 144 citations · Full text

High Price, Healthcare Value, Health Economics +12